MichaelDavidWeissMD

Neurology • Seattle, WA

Neuroimmunology/Multiple Sclerosis, Neuromuscular Medicine

Professor, Neurology, University of Washington School of Medicine

Join to view full profile

Dr. Weiss is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Weiss' full profile

Already have an account?

Office
1959 Ne Pacific St
Box 356115
Seattle, WA 98195
Phone+1 206-598-7688

Fax+1 206-568-7698
Is this information wrong?

Summary

Dr. Michael Weiss is a neurologist in Seattle, WA and is affiliated with University of Washington Medical Center. He received his medical degree from Albert Einstein College of Medicine and has been in practice 26 years. He specializes in neuromuscular medicine and is experienced in general neurology, swallowing disorders, neuromuscular medicine, and clinical neurophysiology.

Education & Training

National Institutes of Health Clinical CenterFellowship, Neuroimmunology & Multiple Sclerosis, 1996 - 2000
University of Maryland Medical Center Midtown CampusNeuromuscular Disease, 1995 - 1996
MedStar Health/Georgetown University HospitalResidency, Neurology, 1992 - 1995
MedStar Health/Georgetown-Washington Hospital CenterInternship, Internal Medicine, 1991 - 1992
Albert Einstein College of MedicineClass of 1991

Certifications & Licensure

WA State Medical License 2001 - 2025
MD State Medical License 1995 - 2001
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Awards, Honors, & Recognition

Top Doctor Seattle Magazine, 2017-2023
Top Doctors Castle Connolly, 2013-2023
Top Doctor Seattle Metropolitan Magazine, 2012-2014, 2017

Clinical Trials

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS) Start of enrollment: 2013 Jul 01
Completed
Phase 2
Therapy in Amyotrophic Lateral Sclerosis (TAME) Start of enrollment: 2018 Nov 07
Completed
Phase 2
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis Start of enrollment: 2016 Oct 01
Completed
Phase 2
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis Start of enrollment: 2017 Oct 11
Completed
Phase 2
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis Start of enrollment: 2019 Sep 17
Completed
Phase 3
Safety Study of Oral Edaravone Administered in Subjects With ALS Start of enrollment: 2019 Nov 18
Completed
Phase 3
Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis Start of enrollment: 2019 Apr 17
Completed
Phase 1
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) Start of enrollment: 2019 Oct 21
Active, not recruiting
HEALEY ALS Platform Trial - Master Protocol Start of enrollment: 2020 Jul 14
Recruiting
Phase 2, Phase 3
HEALEY ALS Platform Trial - Regimen C CNM-Au8 Start of enrollment: 2020 Jul 30
Completed
Phase 2, Phase 3
HEALEY ALS Platform Trial - Regimen A Zilucoplan Start of enrollment: 2020 Jul 29
Completed
Phase 2, Phase 3
HEALEY ALS Platform Trial - Regimen B Verdiperstat Start of enrollment: 2020 Jul 28
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
Leite, M., Maniaol, A., Utsugisawa, K., Bloemers, J., Boroojerdi, B., Howard, E., Savic, N., Howard, J., Weiss, M., Freimer, M.> ;Journal of Neurology. 2024 Feb 24
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study.
James F Howard Jr, Saskia Bresch, Constantine Farmakidis, Miriam Freimer, Angela Genge, Channa Hewamadduma, John Hinton, Yessar Hussain, Raul Juntas-Morales, Henry J K...> ;Therapeutic Advances in Neurological Disorders. 2024 Jan 1
2 citations
Therapeutic targeting of ALS pathways: Refocusing an incomplete picture.
Nicholas J Maragakis, Mamede de Carvalho, Michael D Weiss> ;Annals of Clinical and Translational Neurology. 2023 Nov 1
ALSUntangled No. 16: cannabis.
ALSUntangled Group> ;Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
430 citations
Modern-Day Clinical Course of Type 1 Diabetes Mellitus After 30 Years’ Duration: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions an...
Diabetes Control, Complications Trial, Complications (Dcct), David M. Nathan, Bernard Zinman, Patricia A. Cleary, Jye-Yu C. Backlund, Saul Genuth, Rachel G. Miller, Tr...> ;Archives of Internal Medicine. 2009 Jul 27
Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions.
Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, Lorenzi G, Zinman B, DCCT/EDIC Research Group> ;Diabetes.
125 citations
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;The Lancet. Neurology. 2021 Jul 1
ALSUntangled No. 14: Mototab.
ALSUntangled Group> ;Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
ALSUntangled update 1: investigating a bug (Lyme Disease) and a drug (Iplex) on behalf of people with ALS.
ALSUntangled Group> ;Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
ALSUntangled No. 5: investigating the Stowe/Morales ALS Protocol.
ALSUntangled Group> ;Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
ALSUntangled No. 7: Investigating hyperimmune goat serum (Aimspro) for ALS.
ALSUntangled Group> ;Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
ALSUntangled No. 9: Blue-green algae (Spirulina) as a treatment for ALS.
ALSUntangled Group> ;Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
Cudkowicz M, Genge A, Maragakis N, Petri S, van den Berg L, Aho VV, Sarapohja T, Kuoppamäki M, Garratt C, Al-Chalabi A, REFALS investigators> ;The Lancet. Neurology.
11 citations
Linkage relationships of the protein kinase C gamma gene which exclude it as a candidate for myotonic dystrophy.
Keith J. Johnson, P.J. Jones, N. Spurr, Elaine R. Nimmo, J. Davies, H. Creed, M. Weiss, Robert Williamson> ;Cytogenetics and Cell Genetics. 1988 Jan 1
6 citations
Segregation of linked probes to myotonic dystrophy in a family demonstrating that 152 and APOC2 are on the same side of DM on 19q.
Keith J. Johnson, E. Nimmo, P.J. Jones, M. Weiss, M L Savontaus, Maria Anvret, Richard J. Bartlett, A. D. Roses, D. Shaw, Peter S. Harper, E. Koivunen-Tapio, Robert Wi...> ;Human Genetics. 1988 Dec 1
Paradoxical worsening of anti–myelin-associated glycoprotein polyneuropathy following rituximab.
Weiss MD, Becker P> ;Muscle & nerve.
65 citations
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;JAMA Neurology. 2021 Feb 1
Long-standing Multifocal Motor Neuropathy Presenting With Delayed Clinical Features of Anti-Myelin-Associated Glycoprotein Neuropathy and Elevated Anti-Myelin-Associat...
Bernardo KA, Weiss MD> ;Journal of clinical neuromuscular disease.
3 citations
Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants.
Christopher J Record, Mariola Skorupinska, Matilde Laura, Alexander M Rossor, Davide Pareyson, Chiara Pisciotta, Shawna M E Feely, Thomas E Lloyd, Rita Horvath, Reza S...> ;Brain. 2023 Oct 3
Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis.
Quintana M, Saville BR, Vestrucci M, Detry MA, Chibnik L, Shefner J, Berry JD, Chase M, Andrews J, Sherman AV, Yu H, Drake K, Cudkowicz M, Paganoni S, Macklin EA, HEAL...> ;Annals of neurology. 2023-05-28
21 citations
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Liow, K. K., Howard, J., Bresch, S., Genge, A., Hewamadduma, C., Hinton, J., Hussain, Y., Juntas-Morales, R., Kaminski, H., Maniaol, A., Mantegazza, R., Masuda, M., Si...> ;The Lancet. Neurology. 2023 May 1
7 citations
Novel Variants in theGene Causing Multisystem Proteinopathy 1.
Rod Carlo Agram Columbres, Yue Chin, Sanjana Pratti, Colin Quinn, Luis F Gonzalez-Cuyar, Michael Weiss, Fabiola Quintero-Rivera, Virginia Kimonis> ;Genes. 2023 Mar 8
3 citations
Management of Spinal Muscular Atrophy in the Adult Population.
Nassim Rad, Haibi Cai, Michael D Weiss> ;Muscle & Nerve. 2022 May 1
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.
Paganoni S, Berry JD, Quintana M, Macklin E, Saville BR, Detry MA, Chase M, Sherman AV, Yu H, Drake K, Andrews J, Shefner J, Chibnik LB, Vestrucci M, Cudkowicz ME, Hea...> ;Annals of neurology. 2022-01-10
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.
Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F, REGAIN Study Group> ;Muscle & nerve. 2021-10-14
Join now to see all

Press Mentions

Everything You Know About Muscle Cramps Is WrongDecember 29th, 2018
New Clinical Pilot Studies Will Use Biomarkers to Speed Therapy DevelopmentFebruary 10th, 2016